{"title":"狼疮性肾炎的生物治疗。","authors":"Frédéric A Houssiau","doi":"10.1159/000368587","DOIUrl":null,"url":null,"abstract":"<p><p>This position paper critically analyzes the available controlled data regarding biologic therapy in lupus nephritis (LN). Rather than an exhaustive review of all published evidence, the stress is put on the unmet medical needs in LN, the design of trials aimed at testing the effect of a biologic in LN, the possible reasons for LN trial failures and the future of biological therapy in LN.</p>","PeriodicalId":19094,"journal":{"name":"Nephron Clinical Practice","volume":"128 3-4","pages":"255-60"},"PeriodicalIF":0.0000,"publicationDate":"2014-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1159/000368587","citationCount":"16","resultStr":"{\"title\":\"Biologic therapy in lupus nephritis.\",\"authors\":\"Frédéric A Houssiau\",\"doi\":\"10.1159/000368587\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>This position paper critically analyzes the available controlled data regarding biologic therapy in lupus nephritis (LN). Rather than an exhaustive review of all published evidence, the stress is put on the unmet medical needs in LN, the design of trials aimed at testing the effect of a biologic in LN, the possible reasons for LN trial failures and the future of biological therapy in LN.</p>\",\"PeriodicalId\":19094,\"journal\":{\"name\":\"Nephron Clinical Practice\",\"volume\":\"128 3-4\",\"pages\":\"255-60\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2014-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1159/000368587\",\"citationCount\":\"16\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Nephron Clinical Practice\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1159/000368587\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2014/11/11 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nephron Clinical Practice","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1159/000368587","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2014/11/11 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}
This position paper critically analyzes the available controlled data regarding biologic therapy in lupus nephritis (LN). Rather than an exhaustive review of all published evidence, the stress is put on the unmet medical needs in LN, the design of trials aimed at testing the effect of a biologic in LN, the possible reasons for LN trial failures and the future of biological therapy in LN.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
